Trial Profile
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; Ductal carcinoma
- Focus Therapeutic Use
- 12 May 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health record NCT00496808).
- 12 May 2009 Planned number of patients changed from 20 to 71 as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.